Open AccessPhase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma
Author(s) -
Danielle M. Brander,
David A. Rizzieri,
Jon P. Gockerman,
Louis F. Diehl,
Thomas C. Shea,
Carlos M. DeCastro,
Joseph O. Moore,
Anne Beaven
Publication year - 2013
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/e66e-7q08
Subject(s) - refractory (planetary science) , medicine , vegf receptors , kinase insert domain receptor , diffuse large b cell lymphoma , cancer research , vascular endothelial growth factor , lymphoma , pharmacology , oncology , vascular endothelial growth factor a , biology , astrobiology